# Retatrutide: Research Overview — Peptide Research Alliance > A structured literature summary of Retatrutide (LY3437943), an investigational triple-agonist compound at the GIP, GLP-1, and glucagon receptors. Phase 2 trial results, mechanism, safety profile, and regulatory status. LY3437943 — a 39-amino-acid synthetic peptide engaging GIP, GLP-1, and glucagon receptors simultaneously; not yet approved anywhere; in Phase 3 clinical trials as of mid-2026. ## The short version Retatrutide (research designation LY3437943) is an investigational peptide drug being developed for obesity, type 2 diabetes, and related metabolic conditions. Unlike single-receptor compounds, it is designed to activate three hormone receptors at once: the GIP receptor, the GLP-1 receptor, and the glucagon receptor [8]. This triple-agonist profile is why Phase 2 trials documented body-weight reductions of up to ~24% at 48 weeks — larger than those seen with dual or single agonists [11]. The key facts to hold from the start: Retatrutide is *investigational* — it is not approved by the FDA or any other regulatory agency, and all efficacy and safety data come from clinical trials, not approved labeling. It is in Phase 3 trials (the TRIUMPH program) as of mid-2026. Obtaining it outside a clinical trial means using an unregulated, unverified substance. This page summarizes what the published trial literature shows; it does not recommend use and lists no doses. Retatrutide is sometimes mislabeled in informal discussion as a third glucagon-like peptide — this is a pharmacological misnomer; it acts on the glucagon receptor (GCGR), a distinct receptor that should not be conflated with the GLP-1 or GLP-2 receptor families. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid acyl chain providing albumin binding and an extended plasma half-life suitable for once-weekly dosing. Its molecular formula is C221H342N46O68 (free acid). It is classified as a **GIP/GLP-1/glucagon receptor triple agonist** — the triple-agonist designation reflects simultaneous, single-molecule activity at all three receptors, confirmed by cryo-EM structural analysis [9]. It is an *investigational drug*, not a research chemical in the conventional sense — it has an IND with the FDA, it is being developed by Eli Lilly, and it is under active Phase 3 evaluation. It is not available as a prescription product. Any material sold outside clinical trials under the retatrutide name is of unverified identity and purity. ## How it works Cryo-EM structures published in 2024 resolved retatrutide's binding at all three target receptors — GLP-1R, GIPR, and GCGR — at 2.68 Å, 3.26 Å, and 2.84 Å resolution respectively [9]. Key pharmacological findings from that structural work: retatrutide is approximately 8.9-fold more potent at GIPR than native GIP, and 0.3-fold and 0.4-fold as potent at GCGR and GLP-1R respectively, relative to their native hormones. The mechanistic model is: the **GLP-1 receptor arm** suppresses appetite and slows gastric emptying; the **GIP receptor arm** amplifies glucose-dependent insulin secretion and modulates adipose tissue; the **glucagon receptor arm** increases energy expenditure and fat mobilization through thermogenic and lipolytic mechanisms [8]. This glucagon-driven energy expenditure is the proposed reason for weight loss exceeding that seen with GLP-1-only agents. A dedicated cardiovascular outcomes trial (NCT06383390) is ongoing; cardiovascular and renal effects at scale remain under study. ## What the research shows **Phase 2 obesity trial, 48 weeks (humans, n=338) [11]:** Once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% versus -2.1% for placebo. Gastrointestinal adverse events were dose-related and predominantly mild-to-moderate. A dose-dependent heart-rate increase peaked at approximately 24 weeks. **Phase 2 type 2 diabetes trial, 36 weeks (humans, n=281) [12]:** Retatrutide 12 mg reduced HbA1c by -2.02% at 24 weeks and body weight by -16.94% at 36 weeks, versus -0.01% HbA1c change and -3.00% weight change with placebo. No severe hypoglycemia; no deaths. **Phase 2 metabolic-dysfunction-associated steatotic liver disease substudy, 48 weeks (humans, n=98) [10]:** Among participants with obesity or overweight, no type 2 diabetes, and at least 10% liver fat by MRI-PDFF, retatrutide 12 mg reduced liver fat by -82.4% at 24 weeks; 86% of those participants reached normal liver fat (< 5%). Reductions were sustained to 48 weeks (-86.0% at 12 mg). **Triple-agonist structural confirmation (in vitro, 2024) [9]:** Cryo-EM resolved retatrutide binding at all three target receptors with sub-3-Å resolution. Confirmed differential potency profile versus native hormone agonists. **2025 pharmacology and trial-synthesis review [8]:** Synthesizes the triple-agonist mechanism and Phase 1/2 data, characterizing the up-to-~24% weight loss as a step-change in incretin pharmacology. Reviews GI and heart-rate safety profile and the Phase 3 TRIUMPH program. ## Reported effects, cautions, and safety **Community-reported effects (anecdotal, not clinical evidence)** In research-use communities, the most commonly reported experiences with retatrutide include: near-total suppression of intrusive food thoughts (often called 'food noise going quiet'), rapid and pronounced weight reduction, and a sensation of increased body warmth — attributed in community discussion to the glucagon-receptor arm's thermogenic effect. Elevated resting heart rate is also frequently noted, typically 5–15 bpm above baseline in the hours after administration, consistent with the dose-dependent heart-rate increases documented in Phase 2 trials [11]. Gastrointestinal effects — nausea peaking 4–8 hours post-injection, sulfur burps from slowed gastric motility, constipation, and early-phase fatigue — are among the most common complaints. All community reports are unverified self-reports with no confirmed doses or clinical oversight. **Safety cautions (citation-grounded)** - *Investigational status and unverified supply:* Retatrutide is not approved and remains in Phase 3 trials [8][11]. Material obtained outside trials is of unverified identity and sterility. The FDA issued over 50 warning letters to retatrutide vendors in 2025 for Federal FD&C Act violations. - *Dose-dependent GI adverse events:* In the 48-week Phase 2 obesity trial, nausea affected up to 45% of participants at the highest dose and drove an 18% discontinuation rate at that level [11][12]. Without monitored dose escalation, severe GI events, dehydration, and electrolyte imbalance are plausible risks. - *Heart-rate elevation:* Phase 2 data show mean resting heart-rate increases of approximately 5–7 bpm at the highest doses, peaking at ~24 weeks [11]. The glucagon-receptor arm drives cardiac chronotropy via cAMP/PKA signaling. A dedicated cardiovascular outcomes trial is ongoing. - *Hypoglycemia risk with insulin or sulfonylureas:* Retatrutide augments insulin secretion in a glucose-dependent manner; combined with background insulin or sulfonylureas, severe hypoglycemia is a documented concern. Phase 2 diabetic participants on background insulin required de-escalation [12]. - *Lean mass reduction:* Phase 2 body-composition data confirm retatrutide reduces lean body mass in addition to fat mass during rapid weight loss. The absolute lean-mass reduction in fast-loss contexts is clinically meaningful, particularly for older individuals or those with sarcopenic risk. - *Long-term safety unknown:* All pivotal cardiovascular and renal outcome trials (NCT06383390, NCT05929066, NCT05931367, NCT05882045) are ongoing as of mid-2026. No long-term outcomes data exist. ## Where it fits in this research desk Retatrutide sits in a different scientific category from the other compounds on this desk — it is an investigational *drug* with substantial Phase 2 human clinical data and an active IND, rather than a research chemical or dietary supplement in the conventional sense. Its inclusion here reflects that it is among the most discussed investigational compounds in the research-peptide community and that accurate characterization of its evidence base — including what Phase 2 data can and cannot support about long-term outcomes — is directly useful to researchers and readers following this field. For comparison: BPC-157 has extensive animal data but almost no human trials; Retatrutide has substantial human Phase 2 data but is not yet approved. [Compare all five compounds](/compare) for a systematic view of where each one sits on that evidence spectrum. --- An independent literature digest of peer-reviewed research — definitional, cited, and free of products, prescriptions, and dosing recommendations.